A vial of remdesivir is visually inspected at a Gilead manufacturing site in the US in March. Photo: Gilead Sciences via AP A vial of remdesivir is visually inspected at a Gilead manufacturing site in the US in March. Photo: Gilead Sciences via AP
A vial of remdesivir is visually inspected at a Gilead manufacturing site in the US in March. Photo: Gilead Sciences via AP

Coronavirus pandemic

World /  United States & Canada

Coronavirus: Gilead shares tumble after report that Chinese remdesivir trial flopped

  • Test results showing drug did not make significant difference in likelihood of death or time patients took to improve were posted then quickly removed by WHO
  • Gilead and scientist involved in trial dispute how results were interpreted

Topic |   Coronavirus pandemic
Bloomberg
Bloomberg

Updated: 7:01am, 24 Apr, 2020

Why you can trust SCMP
A vial of remdesivir is visually inspected at a Gilead manufacturing site in the US in March. Photo: Gilead Sciences via AP A vial of remdesivir is visually inspected at a Gilead manufacturing site in the US in March. Photo: Gilead Sciences via AP
A vial of remdesivir is visually inspected at a Gilead manufacturing site in the US in March. Photo: Gilead Sciences via AP
READ FULL ARTICLE